• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    $ICU
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEMD alert in real time by email

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing.

    The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry.

    REGISTER AND VIEW PRESENTATIONS HERE

    The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section.

    Select companies are accepting 1x1 management meeting requests through March 17th.

    Please Schedule 1x1 Meetings here

      March 11th & 12th

     
    PresentationTicker(s)
    SeaStar Medical Holding Corporation(NASDAQ:ICU)
    Nasus Pharma Ltd.(NYSE:NSRX)
    Tonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP)
    Jupiter Neurosciences, Inc.(NASDAQ:JUNS)
    Bora Pharmaceuticals Co., Ltd.(OTCQX:BORAY, TWSE: 6472))
    MetaVia Inc.(NASDAQ:MTVA)
    Phio Pharmaceuticals Corp.(NASDAQ:PHIO)
    Avicanna Inc.(OTCQX:AVCNF, TSX:AVCN)
    EMVision Medical Devices Ltd.(OTC:EMVDF, ASX: EMV))
    Aethlon Medical, Inc.(NASDAQ:AEMD)
    Dyadic International, Inc.(NASDAQ:DYAI)
    Jaguar Health, Inc.(NASDAQ:JAGX)
    Beyond Air, Inc.(NASDAQ:XAIR)
    Cadrenal Therapeutics, Inc.(NASDAQ:CVKD)
    Amplia Therapeutics Ltd.(OTCQB:INNMF, ASX: ATX))
      

    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    johnv@otcmarkets.com



    Primary Logo

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $CVKD
    $DYAI
    $ICU

    CompanyDatePrice TargetRatingAnalyst
    Tonix Pharmaceuticals Holding Corp.
    $TNXP
    6/25/2026$26.00Strong Buy
    Raymond James
    Tonix Pharmaceuticals Holding Corp.
    $TNXP
    5/4/2026$22.00Buy
    TD Cowen
    Dyadic International Inc.
    $DYAI
    10/23/2025$3.00Buy
    H.C. Wainwright
    Dyadic International Inc.
    $DYAI
    9/8/2025Buy
    Craig Hallum
    MetaVia Inc.
    $MTVA
    9/4/2025$12.00Buy
    H.C. Wainwright
    Beyond Air Inc.
    $XAIR
    7/17/2025$11.00Buy
    D. Boral Capital
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $9,900 worth of shares (10,000 units at $0.99), increasing direct ownership by 2% to 421,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/29/26 4:02:13 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Teleman Dan Benjamin bought $20,305 worth of Ordinary Shares (6,550 units at $3.10), increasing direct ownership by 4% to 163,541 units (SEC Form 4)

    4 - Nasus Pharma Ltd (0002029039) (Issuer)

    6/22/26 7:12:42 AM ET
    $NSRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Taylor Carolyn E. bought $14,928 worth of shares (1,415 units at $10.55), increasing direct ownership by 339% to 1,833 units (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    6/15/26 7:00:12 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

    Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarinRecently presented Phase 2 CAD-1005 data demonstrated a >25% absolute reduction in thrombotic events in patients with heparin-induced thrombocytopenia PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of

    7/21/26 8:00:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

    Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that it has entered into a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002. The transaction has a potential value of up to $100 million, including milestone payments, and expands Jupiter from a single-program company into a dual clinical-stage CNS developer. Management believes the transaction strengthens the Company through diversification acr

    7/21/26 7:13:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

    Brings extensive experience in patient care, dermatologic research and commercializationKing of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, and former FDA advisory committee member with more than 30 years of experience in dermatologic care and innovation. He has played a signific

    7/21/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Tonix Pharma with a new price target

    Raymond James initiated coverage of Tonix Pharma with a rating of Strong Buy and set a new price target of $26.00

    6/25/26 8:41:07 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Tonix Pharma with a new price target

    TD Cowen initiated coverage of Tonix Pharma with a rating of Buy and set a new price target of $22.00

    5/4/26 8:35:45 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Dyadic International with a new price target

    H.C. Wainwright resumed coverage of Dyadic International with a rating of Buy and set a new price target of $3.00

    10/23/25 7:06:50 AM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Administrative Officer Rosen Alexander Gustaf Erik converted options into 261,161 shares, increasing direct ownership by 73% to 617,411 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/13/26 4:00:19 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kampf Julie B. converted options into 82,875 shares (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/13/26 4:00:21 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Weis Holger converted options into 85,800 shares, increasing direct ownership by 796% to 96,581 units (SEC Form 4)

    4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

    7/13/26 4:00:14 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    SEC Filings

    View All

    SEC Form 424B3 filed by Jupiter Neurosciences Inc.

    424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    7/21/26 4:07:26 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

    7/21/26 4:05:31 PM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Leadership Update

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    7/21/26 4:05:30 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

    Brings extensive experience in patient care, dermatologic research and commercializationKing of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, and former FDA advisory committee member with more than 30 years of experience in dermatologic care and innovation. He has played a signific

    7/21/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

    Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth JUPITER, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter Neurosciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced the appointment of Tomas J. Philipson, Ph.D., a distinguished health care economist and former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson will serve on both the Audit Committee and Compensation Committee, bringing unparalleled expertise in health economics, reg

    7/7/26 8:58:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Wednesday, June 24, 2026 at 10:30 am ET. This will be a live, interactive online forum where investors are invited to ask the company questions in real-time. If attendees are not able to join the live event on the day of the conference, an archived webcast wi

    6/17/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Financials

    Live finance-specific insights

    View All

    Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

    Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026 The Company is transitioning its year-end from March 31st to December 31st Announced revenue guidance of $8 million for the year ending December 31, 2026 which represents approximately 15% growth; and $16-$18 million or more than 110% growth for the year ending December 31, 2027 Conference call at 8:00 a.m. ET today, June 26th GARDEN CITY, N.Y., June 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of

    6/26/26 7:00:00 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 on Friday, June 26, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day. Conference Call & WebcastFriday, June 26th @ 8:00 a.m. ETDomestic:1-877-407-0784International:1-201-689-8560Conference ID:13761239 Webcast: A webcast of the live confe

    6/22/26 4:01:00 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update

    Australian oncology study advances into Cohort 3 as enrollment continuesEntered the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property portfolio, and maintained a focus on managing operating expenses.Conference Call Today at 4:30 p.m. ETSAN DIEGO, June 10, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment, today reported financial results for its fiscal year ended March 31, 2026, and provided an update on recent developments.  Key Highlight

    6/10/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $CVKD
    $DYAI
    $ICU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:42:22 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:40:17 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care